CytomX conducted a Series A financing with angel investors. In 2010, CytomX completed a $30 million Series B financing led by Third Rock Ventures and including the Roche Venture Fund. In 2012, Canaan Partners led an expansion of the Series B to $41 million.
Third Rock Ventures
Third Rock Ventures is a venture capital firm founded in 2007 with the mission to launch transformative life sciences companies. With more than $1.3 billion and three funds under management, the firm is focused on working with passionate entrepreneurs to build exceptional companies working in areas of disruptive science that will make a difference in the lives of patients.
Roche Venture Fund
The Roche Venture fund invests in early-stage biotech diagnostics companies to develop commercially successful innovative life science companies. Based in Basel with an office in South San Francisco, the Roche Venture Fund invests globally with a portfolio of about 30 companies in 10 countries.
Canaan Partners invests in entrepreneurs and works alongside them to turn visionary ideas into valuable companies. Since 1987, the firm has catalyzed the growth of disruptive technology startups and healthcare companies revolutionizing the practice of medicine. With $3.5 billion under management and more than 85 acquisitions and 53 IPOs to date, Canaan maintains a presence in the global innovation hubs of New York, Silicon Valley, India and Israel.